Oropharyngeal Dysphagia clinical trials at UCSF
1 in progress, 0 open to eligible people
Sorry, not currently recruiting here
The primary objective of this double-blind, randomized, placebo-controlled, multicenter clinical trial is to evaluate the safety of AMDC-GIR during the 24 months following 2 consecutive treatments of tongue dysphagia in male and female patients who have undergone surgery and/or chemo- and/or radiotherapy for squamous cell cancer of the oropharynx.
San Francisco, California and other locations
Our lead scientists for Oropharyngeal Dysphagia research studies include Clark Rosen, MD.